Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

Carlo Perricone; Elena Bartoloni; Roberto Gerli

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology Supplements

Current supplement Archive Rheumatology

Editorial System

Submit your Manuscript

1/2021

Send email

Copy url:

abstract:

Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

Carlo Perricone

¹

,

Elena Bartoloni

¹

,

Roberto Gerli

¹

Rheumatology Unit, Department of Medicine, University of Perugia, Italy

Online publish date: 2021/09/08

View full text Get citation

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].

Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

Carlo Perricone 1 , Elena Bartoloni 1 , Roberto Gerli 1

Carlo Perricone

¹

,

Elena Bartoloni

¹

,

Roberto Gerli

¹